Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)
Condition: Urothelial Bladder Cancer Interventions: Drug: Durvalumab; Drug: Olaparib Sponsors: Spanish Oncology Genito-Urinary Group; AstraZeneca; Sistemas Genómicos; Apices Soluciones S.L. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials